{"organizations": [], "uuid": "faca86855c292a61f7d3666435e47e27be455814", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-bavarian-nordic-announces-phase-2/brief-bavarian-nordic-announces-phase-2-trial-investigating-combination-of-its-immunotherapy-cv301-and-nivolumab-in-microsatellite-stable-colorectal-cancer-idUSASB0C9H0", "country": "US", "domain_rank": 408, "title": "BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-08T16:11:00.000+02:00", "replies_count": 0, "uuid": "faca86855c292a61f7d3666435e47e27be455814"}, "author": "", "url": "https://www.reuters.com/article/brief-bavarian-nordic-announces-phase-2/brief-bavarian-nordic-announces-phase-2-trial-investigating-combination-of-its-immunotherapy-cv301-and-nivolumab-in-microsatellite-stable-colorectal-cancer-idUSASB0C9H0", "ord_in_thread": 0, "title": "BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "nordic a/s - co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News March 8, 2018 / 2:11 PM / Updated 5 minutes ago BRIEF-Bavarian Nordic Announces Phase 2 Trial Investigating Combination Of Its Immunotherapy CV301 And Nivolumab In Microsatellite Stable Colorectal Cancer Reuters Staff 1 Min Read March 8 (Reuters) - Bavarian Nordic A/S: * BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER * BAVARIAN NORDIC A/S - CO, ‍BRISTOL-MYERS SQUIBB AGREE TO SUPPLY CLINICAL MATERIAL FOR TRIAL​ * BAVARIAN NORDIC A/S - ‍PHASE 2 RANDOMIZED TRIAL WILL ENROLL UP TO 74 PATIENTS​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-08T16:11:00.000+02:00", "crawled": "2018-03-08T16:21:43.015+02:00", "highlightTitle": ""}